The platform, described in BMC Cancer, is called StarTrace, and its central idea is deceptively simple. Patient-derived organoids, miniature tumors grown in the laboratory from a patient’s own cancer cells, are already recognized as accurate avatars of the tumors they came from. What StarTrace adds is a way to pool organoids from many different patients into a single dish, expose the entire pool to a drug, and then determine how each patient’s organoid fared. The trick that makes this possible is clonal DNA barcoding: each organoid line is tagged with a unique DNA barcode, one of 72 distinct sequences assembled for the study, that travels with the cells as they grow, divide, and respond to treatment.

Reading out the results relies on a Darwinian logic. When a pool of barcoded organoids is treated with a drug, sensitive organoids die or stop proliferating, so the abundance of their barcodes in the population falls. Resistant organoids keep growing, and their barcodes rise in relative frequency. By comparing barcode abundance before and after treatment, the researchers obtain a quantitative measure of the relative fitness of every organoid in the pool under every drug condition tested. A barcode that drops sharply in frequency after 28 days of exposure to a tyrosine kinase inhibitor flags that patient’s tumor as sensitive; a barcode that holds steady or climbs flags resistance.

Two complementary readout methods track the barcodes. The first is quantitative real-time PCR, a fast and inexpensive assay that can measure the abundance of specific barcode sequences directly. The second is next-generation sequencing, which in this study took the form of single-molecule sequencing assays capable of counting all 72 barcodes simultaneously and deconvoluting the pool over time. The team used the sequencing approach to follow the log-fold change in frequency of each barcoded organoid across a 28-day treatment course, comparing each barcode against a vehicle-treated control. Supplementary data released with the paper include the barcode sequences and their raw counts after each drug treatment, allowing the fitness calculations to be examined in detail.

The organoids themselves came from a biobank of colorectal cancer samples collected under an approved institutional protocol, the Palmetto Health–University of South Carolina Biorepository. Each organoid line was genetically characterized by whole exome sequencing, and somatic mutations in known driver genes were cataloged, with patient-matched normal organoids serving as controls to distinguish inherited variants from tumor-specific ones. The lines included both TP53-mutant and TP53-wildtype organoids, giving the pool a spread of genetic backgrounds against which drug responses could be compared. This genetic annotation matters because one long-term aim of the work is to connect observed drug sensitivity or resistance back to the mutations that cause it, building a map of drug-genetic interactions from real phenotypic data.

The multiplexing is what transforms the economics of the assay. In a conventional organoid drug screen, each patient’s organoids must be plated, treated, and analyzed separately, so testing ten patients against ten drugs requires a hundred independent cultures. In a StarTrace pool, those same hundred data points emerge from a handful of pooled cultures, because every dish contains all ten patients’ organoids at once and each drug condition is tested against the full pool simultaneously. The researchers describe the approach as streamlined and scalable, and the barcode counts from sequencing provide the quantitative depth needed to detect relative fitness changes even when individual organoids grow at different baseline rates within the pool.

The study focused on small molecule inhibitors, including tyrosine kinase inhibitors of the kind widely used in cancer therapy. By tracking relative changes in barcode abundance, the platform compared different patients’ organoid avatars’ responses to the various drugs, generating sensitivity and resistance profiles for each line. The authors note that these comparative response patterns may inform treatment selection in future applications, effectively offering a phase-zero-style phenotypic trial conducted entirely in vitro before any drug reaches the patient. Rather than asking whether a mutation predicts response, the assay asks the tumor itself how it responds, which is the question clinicians actually need answered.

The implications run in two directions. For personalized medicine, a platform that can test a patient’s organoid avatar against a panel of drugs quickly and quantitatively could help oncologists rank treatment options when genetic data alone is ambiguous, a common situation in colorectal cancer where resistance mechanisms are poorly mapped. For preclinical drug development, the same multiplexing logic allows a candidate compound to be screened against dozens of genetically diverse tumor avatars at once, revealing early whether activity is broad or confined to a specific molecular subset. High-throughput screening, phenotypic drug screening, and lab-on-a-chip technologies are all listed among the related subject areas, reflecting where the authors see the platform fitting into the broader research landscape.

The work is early-stage, and the authors are careful about what the current results demonstrate. The published study establishes the quantitative platform and shows that pooled barcode readouts can compare organoid drug responses across patients; clinical validation, prospective trials, and regulatory pathways remain ahead. The team has also moved to protect the invention, filing a U.S. patent application in November 2024 covering the multiplex drug testing platform. Organoid biobanking was supported by an NCI Small Business Innovation Research award, signaling that the group intends to develop the technology toward practical use rather than leave it as a laboratory curiosity.

StarTrace arrives at a moment when organoid technology is maturing from a research tool into a potential clinical decision-support system. Its contribution is architectural rather than biological: by borrowing the barcode-counting logic of modern genomics and applying it to pooled living tumor avatars, it converts drug sensitivity testing from a series of separate experiments into a single scalable measurement. If subsequent studies confirm that pooled barcode fitness readouts predict patient outcomes, the days of choosing cancer therapy by mutation guesswork may be numbered, replaced by a quantitative answer delivered by the tumor itself.

Subject of Research: Multiplex DNA-barcoded organoid avatars for pooled drug sensitivity testing in colorectal cancer

Article Title: StarTrace: a multiplex organoid avatar drug testing platform for personalized medicine

Article References: Khalili, S., Patel, S., Patel, N., Moy, V., Lyons, S., Gray, E., Brents, R., Banister, C. E., Morrison, S. E., & Buckhaults, P. J. (2026). StarTrace: a multiplex organoid avatar drug testing platform for personalized medicine. BMC Cancer. https://doi.org/10.1186/s12885-026-16921-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16921-3

Keywords: patient-derived organoids, colorectal cancer, drug screening, precision medicine, DNA barcoding, high-throughput screening, quantitative PCR, next-generation sequencing, StarTrace, multiplex, organoid, avatar

Current remedies for air leaks are largely mechanical. Synthetic polymer patches, biological grafts such as bovine pericardium and chemical pleurodesis with talc or bleomycin all aim to physically seal the defect or provoke inflammatory adhesions that glue the lung to the chest wall. These measures offer temporary relief but frequently aggravate the problem, triggering foreign body reactions, chronic inflammation and fibrosis that can produce recurrent leaks or pleural adhesions. What has been missing is a therapy that not only plugs the hole but regenerates the pleura’s native structure: a superficial mesothelial monolayer, submesothelial connective tissue and elastic fiber networks that together maintain pulmonary integrity through every breath.

Organoid technology offered the researchers a way forward. Organoids are self-organizing three-dimensional tissue mimics grown from stem cells that replicate the structural and functional complexity of their parent tissue. The approach has already delivered pancreatic islet organoids that restore glucose homeostasis in diabetic models, intestinal organoids that enhance epithelial regeneration after ischemia-reperfusion injury, and liver organoids that mitigate fibrosis by repolarizing macrophages toward a proregenerative phenotype. Yet no one had applied the technology to the pleura, despite its unique mesothelial-stromal interface and its vulnerability to mechanical stress during respiratory cycles.

The team, working at Guangdong Medical University, began with mouse lungs. To avoid contamination with deeper parenchymal cells, they isolated intact lungs without cutting, tied off the trachea and suspended the tissue in collagenase solution, carefully controlling digestion between 30 and 60 minutes. Cells recovered from the pleural surface were embedded in Matrigel and cultured in a medium tuned for mesothelial growth, containing R-spondin, EGF, FGF-10 and Noggin alongside pleural maturation additives such as the TGF-beta receptor inhibitor A83-01, ascorbic acid, retinoic acid and dexamethasone, while reducing the epithelial-supporting factors that drive alveolar and airway differentiation. Within a week, the pleural cells formed organoids with thick walls and a central lumen, clearly distinct from the honeycomb-like alveolar clusters produced by matched lung organoids grown from the same animals.

Molecular profiling confirmed the distinction. Pleura organoids expressed markedly less EPCAM, the pan-epithelial marker, and fewer alveolar markers such as AQP5 and SFTPC or airway markers such as CC10 and p63. Instead, they upregulated mesothelin (MSLN) and calretinin, canonical mesothelial markers, along with vimentin, a stromal and fibroblast marker. Enzyme-linked immunosorbent assays showed that the pleura organoids secreted higher levels of phosphatidylcholine and hyaluronic acid, lubricating substances typically produced by mesothelial cells to keep the pleural cavity gliding smoothly. The organoids retained strong Ki67-positive proliferative activity and could be passaged for more than 20 consecutive passages, a scalability that matters for any future clinical application. The protocol adapted readily to human tissue: pleura-covered areas of surgically resected healthy lung, digested with the pleural surface just submerged in collagenase, yielded human organoids with the same thick-walled morphology, mesothelial marker expression and secretory function, sustained by additions such as nicotinamide, prostaglandin E2 and the GSK3 inhibitor CHIR99021.

To test whether the organoids could form pleura-like structures in a living host, the researchers transplanted human pleura organoid cells beneath the kidney capsule of immunodeficient NSG mice. Three weeks later, a well-organized multilayered structure had formed at the graft site, closely resembling the superficial pleural region of human lung tissue. Verhoeff staining revealed organized collagen and elastic fibers, key components of the visceral pleura, and staining for human nuclear antigen confirmed the structures were built by the transplanted cells rather than by mouse tissue. Crucially, the outermost layer consisted of a continuous sheet of mesothelial cells, validating the structural fidelity of the graft.

Functional testing followed. In Transwell wound-healing assays, adding pleura organoid cells to the upper compartment accelerated the closure of scratches in mesothelial monolayers, even when the inflammatory cytokine TNF-alpha was added to mimic the environment of a fresh wound. The researchers then turned to precision-cut lung slices, 200-micrometer sections of intact lung that preserve the visceral pleura and cellular diversity. Notches cut into the pleural surface simulated pleural rupture, and fluorescently labeled human organoid cells were applied dropwise to the injury. Confocal imaging showed the transplanted cells integrating into the damaged area and, within seven days, forming a continuous, dense, multilayered pleura-like structure on the lung surface composed primarily of mesothelin-positive cells.

The decisive experiment came in living animals. The team punctured the visceral pleura of NSG mice through the chest wall to simulate surgical rupture, then delivered human pleura organoid cells into the pleural cavity. Over 35 days, the transplanted mice gained weight steadily while control mice, which received the carrier medium without cells, lost weight before slowly recovering. Histology showed organoid integration into the lung surface as early as day seven, complete filling of the wound, maturation into a dense multilayered structure by day 21 and progressive remodeling into a looser two-to-three-layered organization by day 35, approaching the single-layer architecture of the native pleura. Immunostaining for mesothelin revealed a continuous mesothelial layer on the lung surface by day seven that remained intact and integrated with the host mesothelium through day 35, and co-localization with human nuclear antigen proved the new lining derived from the graft. Barrier function, quantified by injecting fluid into the trachea and measuring the blast volume, the critical threshold at which fluid leaks past the pleura, was significantly higher in transplanted mice at every time point. Inflammation also subsided: TNF-alpha and IL-6 in alveolar lavage fluid, elevated in injured controls even at day 35, approached normal levels in transplanted animals, and expression of alpha-SMA, a fibrosis marker, was significantly attenuated. Histopathology of the heart, liver, spleen and kidney showed no lesions, indicating the therapy was well tolerated.

Mechanistically, the researchers compared organoids that had engrafted and participated in repair with those that had not. Transcriptome sequencing revealed that CD133, also known as PROM1, a stem and progenitor marker never before investigated in mesothelial contexts, was highly expressed in the transplanted organoids. Flow-sorted CD133-positive cells formed larger and more numerous organoids than CD133-negative cells, and the organoids they generated contained mesothelial, epithelial and stromal lineages, demonstrating multilineage potential, whereas CD133-negative cells differentiated only into epithelial cells. RNA sequencing identified 1,457 differentially expressed genes between the populations, with CD133-positive cells upregulating stemness-associated genes and enriching pathways tied to cell division and distinct metabolic programs. A simplified lineage-tracing experiment tracked mesothelin expression over seven days: CD133-positive organoids showed minimal mesothelin on day one, detectable levels by day three and widespread expression by days five and seven, while CD133-negative cells almost completely failed to become mesothelial cells under identical conditions. Single-cell RNA sequencing of more than 116,000 human lung cells independently confirmed a distinct CD133-positive stem cell subpopulation, positioned at a terminal point of a pseudotime differentiation trajectory, with CD133 expression progressively increasing along the trajectory, and immunostaining localized CD133-positive cells along and adjacent to the pleura in both human and mouse lung under homeostatic conditions.

When CD133-positive and CD133-negative organoids were transplanted into mice with pleural rupture, the difference was stark. CD133-positive grafts nearly maintained body weight, formed larger grafts that continuously covered the pleural wound, markedly increased blast volumes, remodeled collagen and elastic fibers and significantly reduced TNF-alpha and IL-6, while CD133-negative grafts showed only limited repair. In the regenerated tissue, CD133-positive cells co-expressed mesothelin in the surface layer, suggesting direct contribution to mesothelial formation, although the authors note that definitive in vivo lineage tracing is still needed to confirm direct differentiation. The work establishes the first pleura organoid models, identifies CD133-positive cells as a previously unrecognized regenerative population and offers a proof of concept for a progenitor-driven therapy that could one day be personalized: pleural biopsies from patients could generate autologous organoids, mitigating immune rejection while restoring pulmonary homeostasis after surgery.

Subject of Research: Regenerative Medicine

Article Title: Pleura organoid transplantation facilitates visceral pleural repair through CD133+ progenitor cell-mediated regeneration

Article References: Deng, B., Huang, P., Wang, Q., He, Y., Gong, L., Chen, C., Wu, Y., Lu, Z., & Liang, Z. (2026). Pleura organoid transplantation facilitates visceral pleural repair through CD133+ progenitor cell-mediated regeneration. Experimental & Molecular Medicine, 58(9), 2990-3006. https://doi.org/10.1038/s12276-026-01825-w

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01825-w

Keywords: organoids, pleura, CD133, progenitor cells, persistent air leak, mesothelium, lung repair, transplantation, thoracic surgery, regenerative medicine, organoid, facilitates

Standard organoid culture media typically include a basal formulation such as DMEM/F12 supplemented with factors that promote neural differentiation, including N2 and B27 supplements, and often retinoic acid at later stages to encourage photoreceptor maturation. Variations among laboratories in the choice of basal medium, the concentration of supplements, the presence or absence of serum components, and the timing of factor additions have long been recognized as sources of heterogeneity, but the systematic consequences of these choices for downstream applications have been less thoroughly characterized. The finding that media alter both adeno-associated virus transduction and retinal ganglion cell survival suggests that seemingly minor formulation differences can propagate into functional outcomes that matter enormously for translational work.

Adeno-associated virus vectors are the leading platform for retinal gene therapy, with approved products demonstrating that subretinal or intravitreal delivery can produce durable clinical benefit in inherited retinal degenerations. The success of AAV-mediated gene transfer depends on a cascade of events: vector particles must reach the target cells, bind to cell surface receptors, undergo endocytosis, traffic through the cytoplasm, enter the nucleus, uncoat, and convert their single-stranded genome into a transcriptionally competent double-stranded form. Each step can be influenced by the physiological state of the target cell, including membrane composition, endosomal trafficking dynamics, proteasome activity, and the expression of factors that second-strand synthesis. If culture media shift cells into states that favor or hinder any of these steps, then organoid-based assessments of vector tropism and potency will yield results that are artifacts of the culture condition rather than faithful predictions of clinical behavior.

This consideration is particularly acute because organoids are increasingly used as preclinical screening platforms for vector engineering. Researchers seeking capsids with improved photoreceptor tropism, or with the ability to penetrate the inner limiting membrane after intravitreal injection, frequently validate their designs in retinal organoids before advancing to animal studies. A capsid that appears highly efficient in organoids maintained in one medium might underperform in organoids maintained in another, not because the capsid has changed but because the cellular context has. Standardizing media composition, or at minimum reporting it comprehensively and testing key findings across multiple formulations, would strengthen the predictive value of such screens and reduce the risk of pursuing vector designs whose apparent advantages do not survive a change of culture conditions.

The effects on retinal ganglion cell survival are equally consequential. Retinal ganglion cells are the projection neurons of the visual system, conveying visual information from the retina to the brain through the optic nerve, and their degeneration underlies glaucoma and other optic neuropathies. In organoid culture, ganglion cells are notoriously fragile; they are among the first cell types generated, they reside in the innermost layer of the tissue, and they depend on trophic support that is difficult to reproduce in a dish. Their progressive loss during long-term organoid culture is a well-documented limitation, and it complicates any effort to model ganglion cell diseases or to test neuroprotective strategies. If specific medium components can substantially extend ganglion cell survival, this opens two important avenues: first, the creation of longer-lived organoid models in which disease-relevant cell types remain available for study; and second, the identification of the trophic factors and metabolic conditions that ganglion cells require, which may themselves point toward therapeutic targets.

The mechanistic links between medium composition and cell survival likely involve several intersecting pathways. Oxidative stress is a prominent candidate, since retinal neurons are metabolically demanding and vulnerable to reactive oxygen species, and the antioxidant capacity of medium supplements such as those in B27 varies with formulation and with the degradation of components over time in culture. Energy metabolism is another: the retina is among the most oxygen-consuming tissues in the body, and photoreceptors in particular rely on aerobic glycolysis, a metabolic mode whose support depends on glucose and pyruvate availability in the medium. Growth factor signaling, including pathways involving BDNF, CNTF, GDNF, and insulin-like growth factors, also modulates ganglion cell survival, and the presence, stability, and concentration of such factors differ across media formulations. Even the buffering system and the resulting pH stability can influence neuronal health, as can osmolarity and the accumulation of metabolic waste products between medium changes.

For AAV transduction specifically, medium composition might act through effects on the cell surface. The glycocalyx, the dense layer of sugars coating the plasma membrane, provides attachment points that many AAV seruses exploit, and its composition is sensitive to culture conditions, including the availability of specific sugars and the activity of glycosyltransferases. Heparan sulfate proteoglycans serve as primary attachment receptors for several AAV serotypes, and sialic acid residues are critical for others. Media that alter glycosaminoglycan synthesis or sialylation could therefore change the efficiency of the initial binding step. Downstream, intracellular trafficking depends on the cytoskeleton and on endosomal pH, both of which can be modulated by medium components such as ammonium chloride accumulation, chloroquine-like compounds, or simply the energetic state of the cell. These mechanisms offer plausible, testable explanations for how the same vector applied to the same organoid type can perform differently across media.

The broader lesson resonates with a recurring theme in stem cell biology: the environment is part of the experiment. Organoids are often described as miniaturized versions of human tissues, but they are better understood as products of a continuous dialogue between intrinsic developmental programs and the culture environment. Small differences in oxygen tension, media exchange schedules, matrix composition, and the physical handling of cultures have all been shown to affect organoid morphology and cell type composition. The present findings add media formulation to this list in a way that directly touches two of the most translationally important readouts: gene delivery efficiency and survival of a clinically critical neuron.

From a practical standpoint, laboratories working with retinal organoids for gene therapy applications should consider several measures. Detailed documentation of medium composition, including lot numbers of supplements whose activity varies between batches, would improve reproducibility across the field. Cross-validation of key results in at least two distinct media formulations would reveal whether findings are robust or condition-dependent. Where possible, matching the metabolic and trophic environment of the organoid to the physiological state of the target tissue in vivo would improve the clinical relevance of preclinical testing. For ganglion cell studies specifically, optimizing media for survival may need to be balanced against the goal of photoreceptor maturation, since conditions that favor one cell class may not favor another, and the developmental timing of these requirements may differ.

There are also implications for disease modeling. Many inherited retinal diseases are cell-type specific, and the value of an organoid model depends on maintaining the relevant cells in a state that resembles their in vivo counterpart. Ganglion cell loss in culture has limited the use of organoids for modeling optic neuropathies such as those caused by mutations in OPA1 or other genes affecting mitochondrial function. If optimized media extend ganglion cell survival substantially, models of these diseases become feasible, enabling the study of pathogenesis in a human developmental context and the screening of candidate neuroprotective compounds. Similarly, for glaucoma research, where the interplay between elevated intraocular pressure, axonal transport disruption, and somal survival is difficult to disentangle in animal models, longer-lived organoid systems with robust ganglion cell populations would provide a complementary human platform.

The intersection with AAV biology deserves particular attention as the gene therapy field matures. Dose-limiting toxicity, immune responses, and the challenge of achieving pan-retinal transduction after intravitreal delivery remain central obstacles. Organoids offer a human-relevant system in which to evaluate candidate capsids, promoters, and expression cassettes, but their utility depends on the transduction results reflecting what would occur in a patient retina. The finding that media promote or suppress transduction suggests that part of the variability reported across organoid studies of AAV tropism may be attributable to culture conditions rather than to genuine differences in vector performance. Disentangling these variables will require systematic comparisons in which identical vectors are applied to organoids raised in parallel under different media conditions, with careful quantification of both transduction efficiency and the cell-type composition of the tissues.

It is also worth considering how these findings fit into the larger regulatory and manufacturing landscape. As retinal organoids move toward use in potency assays and release testing for cell and gene therapy products, the dependence of their properties on media composition becomes a matter of product consistency. Regulatory frameworks emphasize the characterization of critical quality attributes, and for organoid-based assays, the culture medium is arguably a critical reagent whose composition must be controlled with the same rigor as the biological material itself. Manufacturers of media and supplements may need to provide more detailed specifications, and users may need to implement qualification procedures for each new lot, particularly for supplements such as B27 whose complex composition includes components with variable biological activity.

Looking forward, the systematic mapping of how individual medium components affect retinal organoid physiology could yield a design framework for culture conditions tailored to specific applications: media optimized for photoreceptor maturation for studies of inherited photoreceptor degenerations, media optimized for ganglion cell survival for optic neuropathy models, and media that support efficient AAV transduction for vector validation studies. Such an approach would treat the medium as an engineering variable rather than a fixed convention, transforming a source of uncontrolled variability into a tool for shaping organoid properties. The present work, by demonstrating that culture media alter both AAV transduction and retinal ganglion cell survival in retinal organoids, provides both a caution about the interpretation of existing organoid studies and a constructive starting point for this more deliberate approach to organoid culture design.

Subject of Research: Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival

Article Title: Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival

Article References: O’Hara-Wright, M., Lim, B. Y., M. Mangala, M., Kaiser, V., Wong, E., Aubin, D., Nemeruck, V., Reynisson, H., Doroudian, F., Chan, O. P. Y., Aryamanesh, N., A. Paulo, J., Palomba, S., Mirzaei, M., Ginn, S. L., & Gonzalez-Cordero, A. (2026). Culture media alter retinal organoid physiology promoting AAV transduction and retinal ganglion cell survival. Gene Therapy. https://doi.org/10.1038/s41434-026-00642-0

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00642-0

Keywords: Culture, media, alter, retinal, organoid, physiology, promoting, transduction, ganglion, cell, survival, scientific research